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Summary
The manageable toxicity profile of obinutuzumab (GA101; G) alone or
with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory
(R/R) patients with chronic lymphocytic leukaemia (CLL) was established
in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov:
NCT01905943). The final analysis (cut-off, 31 January 2019) is reported
here. Patients received G (1000 mg) alone (G-mono; fit and non-fit
patients) or with chemotherapy [fludarabine and cyclophosphamide (FC;
fit patients); chlorambucil (non-fit patients); bendamustine (any patient)].
Study endpoints were safety (primary) and efficacy (secondary). Subgroup
analyses were performed on prognostic biomarkers in 1L CLL. Overall, 630
patients received 1L and 341 received R/R CLL treatment. At the final anal-
ysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs):
1L 827%, R/R 845%; serious AEs: 1L 581%, R/R 625%]. Neutropenia
(1L 505%, R/R 534%) and thrombocytopenia (1L 146%, R/R 191%)
were the most common Grade 3–5 AEs. G-mono-, G-bendamustine and G-
FC-treated patients with unmutated immunoglobulin heavy chain trended
towards shorter progression-free survival. Achievement of minimal residual
disease negativity was greatest in 1L patients treated with G-FC. In this
final analysis of the GREEN trial, the safety profile of G was consistent with
current risk management strategies. Biomarker analyses supported efficacy
in the specific subgroups.
Keywords: Obinutuzumab, chronic lymphocytic leukaemia, safety, IGHV,
minimal residual disease.
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Introduction
Over the past decade, chemoimmunotherapy has played a key
role in the management of chronic lymphocytic leukaemia
(CLL), with rituximab established as the backbone of
chemoimmunotherapy for managing patients with previously
untreated first-line (1L) CLL.1–4 Frontline rituximab with flu-
darabine and cyclophosphamide (FCR) has been the standard
of care for physically fit (≤65 years) CLL patients.5,6 Rituximab
plus bendamustine (Benda-R) is often given to fit patients aged
≥65 years who are at higher risk of infections.6 The potential
toxicities of FCR have also led to the use of chlorambucil (Clb)
plus obinutuzumab (GA101; G) as frontline chemoim-
munotherapy for elderly patients (≥65 years) with reduced fit-
ness and/or relevant comorbidities, as Clb is not associated
with a higher infection rate.7–9 G-Clb is preferred over ritux-
imab-Clb because of its superior efficacy and higher rate of
minimal residual disease (MRD)-negativity.10–13
Chemotherapy-free options are important for frail, elderly
patients who cannot tolerate chemotherapy,14 and for patients
with genetic characteristics such as del17p, TP53mut and
unmutated immunoglobulin heavy chain (IGHV), who show
poor outcomes with chemoimmunotherapy.15 Recently, the
US Food and Drug Administration approved G plus ibruti-
nib,16,17 venetoclax,18,19 and acalabrutinib.20,21 Despite these
advances, chemoimmunotherapy is still considered to have an
important role in CLL treatment, especially in patients with
mutated IGHV, who reportedly receive sustained benefit from
chemoimmunotherapy.16,22–24 It, therefore, remains important
to further investigate the safety of chemoimmunotherapy and
to define the subgroups that derive particular benefit.
The GREEN trial (NCT01905943) is a safety study of G,
alone or in combination with chemotherapy, in a broad pop-
ulation of CLL patients.25,26 It was mandated by regulatory
authorities following the approval of G in CLL; the primary
safety analysis has been published previously.27 Here, we
report the final safety and efficacy analysis from the overall
GREEN population, with 18 months additional follow-up.
The potential value of prognostic biomarkers (IGHV, cytoge-
netic abnormalities and CD38 expression) in 1L and R/R
patients was also evaluated.
Methods
Study design
The GREEN study is a non-randomised, four-cohort, open-
label, international, multicentre Phase IIIb safety study. The
study design and inclusion/exclusion criteria have been
described previously.27 The study was conducted according
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to the Declaration of Helsinki, Good Clinical Practice guide-
lines and local regulations. The study protocol (and amend-
ments) were approved by participating centre review boards/
ethics committees. Patients provided written informed con-
sent to participation.
Patients and treatment
Patients with 1L or R/R (≤3 prior therapies) CLL received
intravenous G (1000 mg split over 2 days) alone [G-mono;
fit (Cumulative Illness Rating Scale; CIRS) ≤6 and creatinine
clearance (CrCl) ≥70 ml/min] or non-fit patients (CIRS > 6
and/or CrCl < 70 ml/min) or in combination with
chemotherapy, as selected by the investigator [intravenous or
oral FC (fit patients), oral Clb (non-fit patients); or intra-
venous Benda (fit and non-fit patients)]. Dosing details are
provided in Appendix S1.
Study endpoints and assessments
The current analysis aimed to detail safety post-final response
assessment visit (FRA; 3 months after last dose of study
treatment) and frequently reported Grade ≥ 3 adverse events
(AEs) until 24 months after the end of treatment, serious
AEs (SAEs), AEs of special/particular interest (AESI/AEPI),
AEs leading to death and efficacy data.
Efficacy outcomes included best overall response (BOR),
duration of response (DoR), progression-free survival (PFS),
overall survival (OS), time-to-next-anti-leukaemia-treatment
(TTNT), duration of MRD negativity, MRD-negative status
at the FRA and patient-reported outcomes (PROs). Assess-
ment details are provided in Appendix S1.
Exploratory endpoints included central prognostic marker
analysis (IGHV mutation status, genetic aberrations (del
(11q), trisomy 12q, del(13q), del(17p) and CD38 expression))
in relation to efficacy (1L patients: PFS, OS and TTNT; 1L
and R/R patients: objective response rate and MRD]).
Statistics
The GREEN study was non-comparative with no formal sta-
tistical testing and no power calculation. The final analysis
was performed at the end of the study, which was 30 months
after enrolment of the last patient, or sooner, if one of the
following was documented for all treated patients: with-
drawal from the study, loss to follow-up, death or study ter-
mination (data cut-off 31 January 2019).
Safety analyses were based on the safety population (pa-
tients who received ≥1 dose of study treatment). Efficacy
analyses were performed in the intent-to-treat (ITT) popula-
tion (all enrolled patients, regardless of whether they received
treatment). Time-to-event variables (PFS, OS and TTNT)
were presented graphically using KaplanMeier plots, and by
prognostic markers. Patient-reported outcome endpoints
were summarised at baseline and over time. MRD analyses
were performed on the intent-to-ship (ITS) population,
which comprised all patients from the ITT population with
MRD samples (bone marrow [BM] and/or peripheral blood
[PB]) at the FRA that could be shipped to the central labora-
tory within 48 h of sampling. Because of the exploratory nat-




Overall, 972 patients were enrolled in the GREEN study
between October 2013 and March 2016 at 195 centres in 31
countries (ITT population; 1L 631 patients, R/R 341
patients); 789 (812%) patients completed all study treat-
ments per the protocol. With the exception of one non-fit
patient in the 1L group, all enrolled patients received ≥ 1
dose of the study drug and were included in the safety popu-
lation (n = 971) (Figure S1).
Baseline demographics and disease characteristics are
shown for the ITT population in Table I, and for 1L patients
according to treatment and fitness status in Table SI. Treat-
ment exposure is summarised in Table SII.
Safety
Median observation time was 437 months (range 03–592
months) and the median follow-up time across the four
treatment arms in each patient group was 40–50 months.
In the safety population, 986% of 1L and 985% of R/R
patients reported ≥ 1 any-grade AE, and 827% and 845%
respectively, experienced Grade ≥ 3 AEs. The incidence of
any-grade AEs and Grade ≥ 3 AEs was similar across treat-
ments (Table II).
The most common Grade ≥ 3 AEs (≥ 10% of patients in
the 1L or R/R group) were neutropenia (1L 505%, R/R
534%), thrombocytopenia (1L 146%, R/R 191%), anaemia
(1L 89%, R/R 120%) and pneumonia (1L 84%, R/R
152%). SAEs occurred in 581% of 1L and 625% of R/R
patients (Table II).
The most frequent SAEs (≥ 10% of patients in the 1L or
R/R group) included pneumonia (1L 87%, R/R 158%) and
neutropenia (1L 100%, R/R 123%).
Any-grade AESI/AEPI are summarised by treatment regi-
men in Table II. Grade ≥ 3 infusion-related reactions
occurred in 194% of 1L patients and 196% of R/R patients.
The most common infections were pneumonia (1L 125%;
R/R 185%), bronchitis (1L 73%, R/R 97%) and upper res-
piratory tract infection (1L 70%, R/R 91%); 27% of 1L and
70% of R/R patients had a Grade 5 infection. Overall, 146%
of 1L and 158% of R/R patients prematurely discontinued G
treatment because of AEs.
Tumour lysis syndrome (TLS) occurred in 75% of 1L and
47% of R/R patients; TLS incidence was slightly higher
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among non-fit (107%) vs. fit patients (47%). All patients
with TLS experienced the AE only once during the study. Of
the safety population (n = 971), 33% of patients had labora-
tory TLS and 32% had clinical TLS. All TLS AEs (except
one Grade 1 AE) were Grade ≥ 3; overall, 38 patients had
serious TLS events (1L 43%; R/R 32%). Two patients in the
1L G-Benda subgroup died as a result of TLS, one fit patient
with lymphadenopathy and one non-fit patient with chronic
renal failure and bulky disease; both died from cardiac
events. Subsequent TLS risk minimisation measures were
implemented (Table SIII).
In total, 80 1L (127%) and 107 R/R (314%) patients in
the safety population died (Table III); 70 (72%) patients
died from progressive disease (1L 38%, R/R 135%) and 117
(120%) died from AEs (1L 89%, R/R 179%). Fatal AEs
reported in > 1% of patients were for system organ classes of
infections and infestations [1L 27%, (n = 17); R/R 70%
(n = 24)], neoplasms [1L 25% (n = 16); R/R 44%
(n = 15)] and general disorders and administration site con-
ditions [1L 25% (n = 16); R/R 44% (n = 15)]. The most
commonly reported fatal AE by preferred term was pneumo-
nia [1L 10% (n = 6); R/R 29% (n = 10)].
Efficacy
Response rates at the FRA and median DoR for 1L and R/R
patients are summarised in Table IV. For 1L patients, med-
ian PFS was not reached in the G-FC group, and was
580 months in the G-Benda group, 302 months in the
G-mono group and 318 months in the G-Clb group
(Table IV and Fig 1). At the time of final analysis, median
OS was not reached with any regimen. The 4-year OS rate
was highest in the G-FC arm (Table IV and Fig 2). Median
TTNT was not reached in 1L patients treated with G-FC, G-
Benda or G-mono and was 537 months for 1L patients trea-
ted with G-Clb (Table IV and Fig 3).
Patient reported outcomes remained unchanged or
improved over the course of the study and are reported in
Appendix S1 and Table SIV).
MRD
From the ITS MRD assessment population (n = 811), 544
and 354 patients had MRD samples at the FRA from PB and
BM respectively, available for analysis (Table SV). Of these,
536 and 275 patients were in the 1L and R/R groups respec-
tively. MRD negativity rates were highest for 1L patients
treated with G-FC (PB, 708%; BM, 401%) and G-Benda
(PB, 642%; BM, 294%) (Table IV).
Median duration of MRD negativity in PB (based on
patients in the ITT population with an MRD-negative result)
was similar for 1L patients treated with G-Benda, G-FC and
G-Clb (163–182 months) and was shorter in 1L G-mono-
treated patients (101 months) and in R/R patients for all
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Any death 28 (220) 36 (316) 103 (192) 20 (104) 187 (193)
<28 days after last study treatment 2 (16) 3 (26) 7 (13) 0 12 (12)
In follow-up phase 26 (205) 33 (289) 96 (179) 20 (104) 175 (180)
Death related to G 0 4 (35) 10 (19) 2 (10) 16 (16)
Primary cause of death:
PD 11 (87) 16 (140) 34 (63) 9 (47) 70 (72)
AE 17 (134) 20 (175) 69 (128) 11 (57) 117 (120)
Underlying CLL a contributing factor 8 (471) 6 (300) 28 (406) 5 (455) 47 (402)
AE, adverse event; Benda, bendamustine; Clb, chlorambucil; FC, fludarabine/cyclophosphamide; G, obinutuzumab; mono, monotherapy; PD, pro-
gression of disease. Values are n (%).
Table IV. Overview of key efficacy results at the FRA (investigator assessment).




























































































































DoR* n = 49 n = 39 n = 64 n = 39 n = 322 n = 165 n = 147 n = 39
















MRD status at FRA in PB† n = 50 n = 49 n = 53 n = 32 n = 296 n = 161 n = 137 n = 33
MRD-negative, n (%)‡ 8 (160) 2 (41) 5 (94) 2 (63) 190 (642) 64 (398) 97 (708) 17 (515)
MRD status at FRA in BM† n = 50 n = 49 n = 53 n = 32 n = 296 n = 161 n = 137 n = 33
MRD-negative, n (%)‡ 2 (40) 1 (20) 3 (57) 1 (31) 87 (294) 24 (149) 55 (401) 8 (242)
Duration of MRD negativity§ n = 13 n = 2 n = 7 n = 3 n = 220 n = 74 n = 117 n = 17
















1L, first-line; Benda, bendamustine; BM, bone marrow; BOR, best overall response; CI, confidence interval; Clb, chlorambucil; CR, complete
response; CRi, complete response with incomplete bone marrow recovery; DoR, duration of response; FC, fludarabine/cyclophosphamide; FRA,
final response assessment; G, obinutuzumab; ITS, intention-to-ship; mono, monotherapy; MRD, minimal residual disease; N/A, not available; OS,
overall survival; PB, peripheral blood; PFS, progression-free survival; PR, partial response; R/R, relapsed/refractory; TTNT, time to new (anti-leu-
kaemia) therapy.
*Patients with BOR of CR, CRi, or PR.
†Intent-to-Ship population.
‡BM samples were only collected from patients with a CR or CRi at the FRA; PB samples for MRD analysis were collected from all patients with
PR or CR, where possible. The proportion of patients with an MRD-negative result was calculated for the ITS population.
§Duration of MRD negativity is bsased on patients in the ITT population with an MRD-negative result in PB.
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Fig 1. KaplanMeier plot of progression-free survival (intent-to-treat population) in previously untreated and relapsed/refractory/patients treated
with (A) obinutuzumab (G) bendamustine (B) G-mono, (C) G- chlorambucil; and (D) G- fludarabine/cyclophosphamide
Fig 2. KaplanMeier plot of overall survival (intent-to-treat population) in previously untreated and relapsed/refractory patients treated with (A)
obinutuzumab (G) bendamustine (B) G-mono, (C) G- chlorambucil and (D) G- fludarabine/cyclophosphamide
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should be noted that the sample size for some of the sub-
groups was very small (Table IV).
Biomarker analysis
PFS, OS and TTNT according to IGHV mutation status are
shown in Fig 4. Unmutated IGHV status was associated with
a trend towards shorter PFS (Fig 4A). Unmutated IGHV was
also associated with a trend towards less favourable OS and
TTNT (Fig 4B–C).
PFS for patients with genetic aberrations is shown accord-
ing to 1L treatment regimen in Fig S2A. Patients with the del
(13q) and trisomy 12q aberrations, according to the hierar-
chical model, had the most favourable outcome, while
patients with the del(17p) and del(11q) aberrations had the
least favourable outcome. For OS and TTNT, del(17p) was
also associated with the least favourable outcome of all
genetic aberrations assessed (Figs S3A and S4A).
CD38 + expression was associated with a trend towards a
shorter PFS (Fig S2B). Absence of CD38 expression was asso-
ciated with a trend towards more favourable OS and TTNT
(Figs S3B and S4B).
The objective response rate at the FRA by prognostic
markers in 1L and R/R patients according to treatment
received is detailed in Table SVI. MRD negativity at FRA in
PB and BM by prognostic markers is presented in
Tables SVII and SVIII.
Discussion
The GREEN study final analysis provides further evidence to
support G-Clb as a treatment option for non-fit, 1L patients
with CLL. It also supports G-Benda and G-FC as potential
treatment options for fit and non-fit 1L CLL and for R/R
CLL patients who are eligible to receive chemoimmunother-
apy. Our subgroup analyses confirm that chemoimmunother-
apy is an efficacious treatment in certain groups, for
example, mutated IGHV and non-del(17p)/del(11q). No new
safety signals were reported during the additional follow-up.
The safety data support the findings of previous studies
with G.11,13,28–32 Fatal AEs were reported in 18% of R/R
patients (fatal infections in 7%), indicating that caution is
needed when choosing therapy for R/R patients. Phase III
studies of anti-CD20 therapy plus novel agents in R/R CLL
show lower rates of fatal AEs than those seen with chemoim-
munotherapy in the GREEN study (2–10%).20,33,34
Grade ≥ 3 TLS occurred in 73% of 1L and 47% of R/R
patients in the GREEN study. This was higher than the rates
of TLS reported in the CLL14 trial (1L CLL: 14% in G-vene-
toclax-treated patients and 23% in G-Clb-treated patients).18
In view of the potential risk of TLS, risk mitigation strategies
should be used to minimise the occurrence of TLS with G in
clinical practice.26 The two deaths from TLS (in 1L patients)
in the current study highlight the importance of awareness of
TLS symptoms and implementation of these strategies.
Fig 3. KaplanMeier plot of time to next (anti-leukaemia) treatment (intent-to-treat population) in previously untreated and relapsed/refractory
patients treated with (A) obinutuzumab (G) bendamustine, (B) G-mono, (C) G-chlorambucil and (D) G- fludarabine/cyclophosphamide.
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Fig 4. KaplanMeier plots of progression-free survival (A), overall survival (B) and time to next anti-leukaemia treatment (C) by immunoglobu-
lin heavy chain mutation status in patients with chronic lymphocytic leukaemia who received first-line obinutuzumab (G)-mono, G ben-
damustine (Benda), G- fludarabine/cyclophosphamide (FC) or G-chlorambucil (Clb). PFS, progression-free survival; OS, overall survival.
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The high response rates reported across all settings and
regimens in the current study are consistent with previous
findings demonstrating the promising benefit–risk profile of
chemoimmunotherapy as well as G-mono, in patients with
1L and R/R CLL.5,6,10-13,22,26,28-32,35–38 The BOR rate was
within the expected range for CLL patients across the four
regimens. Biomarker analysis was not prognostic for response
rate; this may be due in part to the generally small patient
subgroups.
Median PFS, OS and TTNT were not reached for 1L treat-
ment with G-FC and were 58 months, not reached, and not
reached respectively, for 1L G-Benda. Of note, G-FC was
only administered to fit patients, whereas both fit and non-
fit patients received G-Benda; therefore, the non-fit patients
may have compromised the outcome of the G-Benda regi-
men. Time-to-event outcomes in G-mono-treated patients
were comparable with outcomes in patients treated with G-
Clb. Although not approved for CLL, it raises the question
as to whether G-mono is a potentially useful treatment
option for patients who want chemotherapy-free options, or
for debulking prior to novel agents.
Mutated IGHV trended towards more favourable PFS
compared with IGHV-unmutated status in all treatment
groups, similar to findings from the ALLIANCE trial of
rituximab-ibrutinib vs. Benda-R in older 1L CLL patients;23
similarly, there was a trend towards worse OS and TTNT in
patients with unmutated IGHV. A retrospective review of
404 CLL patients who received FCR as frontline chemoim-
munotherapy found unmutated IGHV, del(11q) and del(17p)
to be independently associated with PFS.22 The authors
found that patients with mutated IGHV and without del
(11q) or del(17p) had a progressive reduction in risk of
relapse from 4 years after FCR treatment, and had a similar
life expectancy to the matched normal population.22 Simi-
larly, a follow-up of 300 patients from a Phase II study of
FCR, at a median of 128 years posttreatment, found that
mutated IGHV status was significantly associated with MRD
negativity, and that unmutated IGHV was associated with
inferior PFS and OS.39 The authors noted that patients with
mutated IGHV who achieved MRD negativity had excellent
outcomes, with extended remissions.
In the current study, 1L patients with del(13q) and tri-
somy 12q experienced PFS comparable to patients with no
abnormality, consistent with results from the CLL14 trial,
which showed reduced PFS in all cytogenetic, high-risk sub-
groups, except trisomy 12q.18 Del(11q) and, in particular, del
(17p) trended towards worse PFS among all treatment
groups, except for G-mono, where patients with trisomy 12q
had worse PFS than patients with a normal karyotype. Lack
of CD38 expression trended towards better PFS in all treat-
ment groups, except in patients treated with G-FC. Del(17p)
trended towards worse OS, whereas patients with del(13q),
trisomy 12q, or del(11q) had comparable OS to patients with
no abnormality. There was a trend toward worse OS for
patients with CD38 expression, particularly in the G-mono
group. Del(17p) showed a trend for the worst TTNT among
the four molecular aberrations in all treatment groups. There
was a trend towards worse TTNT for patients with CD38
expression, for all treatment groups. Therefore, our findings
show that del(17p) and CD38 expression may be prognostic
for poor PFS, OS and TTNT among all treatment groups,
consistent with the published literature, and may identify
candidate populations for treatment with novel agents.40–42
Baseline levels of quality of life (QoL), physical function-
ing and fatigue remained stable or improved over the course
of treatment. CLL and its treatments can profoundly affect
QoL, particularly in R/R patients; it is encouraging that the
combinations explored here indicated no deterioration in
QoL with the G-based combinations.
There is currently a lack of available treatment options for
patients with R/R CLL who have experienced multiple
relapses. Recently, anti-CD20 antibody-based, fixed-duration
chemotherapy-free approaches have demonstrated efficacy in
this setting in the MURANO trial.43 Given that G has
demonstrated greater efficacy than rituximab in other CLL
studies,10–13 it could be assumed that G may be the preferred
backbone/partner in future novel combination therapies for
patients with R/R CLL. Of note, G is already approved in
combination with ibrutinib,16,17 venetoclax,18,19 and acal-
abrutinib20,44 for patients with 1L CLL. However, it should
be noted that rituximab-Clb and G-Clb are approved, and
rituximab-based and G-based chemoimmunotherapy is
widely available in North America and Europe. This contrasts
with the newer chemotherapy-free options (e.g., ibrutinib
and venetoclax), which may not be readily available in some
countries, especially when treatment duration is unlimited.
Furthermore, a substantial proportion of patients discontinue
frontline ibrutinib because of toxicity.45 Moreover, there is a
proportion of CLL patients with a favourable genetic profile
who can, potentially, achieve a functional cure with 1L
chemoimmunotherapy.
As described previously,27 the GREEN study had several
limitations, including the non-comparative/non-randomised
study design and potential investigator bias on patient alloca-
tion to cohorts/treatment, preventing the direct comparison
of specific regimens, and resulting in difficulty interpreting
biomarker data because of small patient subgroups. However,
as most investigators followed current guidelines when select-
ing treatment,1,3 this under-representation was as expected.
All patients were analysed as treated, meaning that the G-
mono group included patients who discontinued treatment
because of AEs after their first dose of G before receiving
their planned chemotherapy regimen, as well as patients who
were only ever scheduled to receive single-agent G, resulting
in higher than expected rates of AEs and discontinuations
due to AEs in this group.28,30
This final analysis of the GREEN study supports G plus
chemotherapy, beyond the approved G-Clb regimen, as a
promising treatment option in both 1L and R/R CLL, irre-
spective of the partner chemotherapy. It also highlights the
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benefit of a 1L chemoimmunotherapy regimen for patient
subgroups defined by genetic markers and mutated IGHV
status.
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markers (cytogenetic abnormalities, CD38 and IGHV) in 1L
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G-FC or G-Clb
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prognostic markers (cytogenetic abnormalities, CD38, and
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FRA by prognostic markers (cytogenetic abnormalities, CD38
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mono, G-Benda, G-FC or G-Clb.
Fig S1. Patient flow diagram.
Fig S2. KaplanMeier plots of PFS by prognostic markers
in patients with CLL who received 1L G-mono, G-Benda, G-
FC or G-Clb: (A) cytogenetic abnormalities (B) CD38. 1L,
first-line; Benda, bendamustine; CI, confidence interval; Clb,
chlorambucil; FC, fludarabine/cyclophosphamide; G, obinu-
tuzumab; HR, hazard ratio; mono, monotherapy; PFS, pro-
gression-free survival; R/R, relapsed/refractory.
Fig S3. KaplanMeier plots of OS by prognostic markers
in patients with CLL who received 1L G-mono, G-Benda, G-
FC or G-Clb: (A) cytogenetic abnormalities (B) CD38. 1L:
first-line; Benda, bendamustine; CI: confidence interval; Clb:
S. Stilgenbauer et al.
336 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd.. British Journal of Haematology, 2021, 193, 325–338
chlorambucil; FC: fludarabine/cyclophosphamide; G: obinu-
tuzumab; HR: hazard ratio; mono: monotherapy; OS: overall
survival; R/R: relapsed/refractory.
Fig S4. KaplanMeier plots of TTNT by prognostic mark-
ers in patients with CLL who received 1L G-mono, G-Benda,
G-FC or G-Clb: (A) cytogenetic abnormalities (B) CD38.
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